Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension

Published:1997-01 Issue:1 Volume:15 Page:93-97
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:Journal of Hypertension

Author:

Küppers Hartmut E.,Jäger Bodo A.,Luszick Joachim H.,Gräve Michael A.,Hughes Peter R.,Kaan Elbert C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference11 articles.

1. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension

2. Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects

3. Circadian variation in the incidence of sudden cardiac death in the framingham heart study population

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Not first‐line antihypertensive agents, but still effective—The efficacy and safety of imidazoline receptor agonists: A network meta‐analysis;Pharmacology Research & Perspectives;2024-05-28

2. Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement;Journal of Hypertension;2024-05-15

3. Modern ideas about the consequences of sympathoadrenal hyperactivation in hypertensive patients with metabolic disorders: modulation possibilities;Russian Journal of Cardiology;2023-12-19

4. Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II;Cardiovascular Therapy and Prevention;2021-10-16

5. Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis;Terapevticheskii arkhiv;2021-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3